{"schema_version":"1.0","type":"article","title":"Ozempic Face Is a Fat Gap, and Galderma Is Filling It","url":"https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra-en.md","lang":"en","date":"2026-10-26","publish_at":"2026-10-26T08:00:00+08:00","updated_at":"2026-10-26","category":"商業分析系列","topic":"商業分析系列","tags":["Ozempic face","GLP-1 facial volume loss","Sculptra","Galderma","Caliway CBL-514"],"summary":"GLP-1 users are losing facial fat, not collagen, so creams can't fix 'Ozempic face.' Galderma's fillers and biostimulators grew 10.5% in H1 2026 while AbbVie's Juvéderm fell 6.6% in Q2.","key_points":["'Ozempic face' from GLP-1 weight loss is a loss of facial fat, not collagen, so creams cannot fix it; Galderma's 2026 full-year Fillers & Biostimulators sales will grow at least 8% at constant currency while AbbVie's Juvéderm declines for the year.","Galderma's Fillers & Biostimulators sales reached $611 million in the first half of 2026, up 10.5% at constant currency, while AbbVie's Juvéderm sold $245 million in Q2 2026, down 6.6% operationally.","A KFF poll in November 2025 found 18% of U.S. adults had taken a GLP-1 drug, and BCG estimates treatments for facial volume loss and skin laxity will grow from about $700 million to $2 billion over five years."],"facts":[{"claim":"Share of U.S. adults who have ever taken a GLP-1 drug (KFF poll)","value":18,"unit":"%","as_of":"2025-11-14","source":"https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/"},{"claim":"Share of U.S. adults currently taking a GLP-1 drug (KFF poll)","value":12,"unit":"%","as_of":"2025-11-14","source":"https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/"},{"claim":"Current GLP-1 use among U.S. adults aged 50-64","value":22,"unit":"%","as_of":"2025-11-14","source":"https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/"},{"claim":"Galderma H1 2026 net sales","value":3134,"unit":"million USD","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma H1 2026 net sales growth at constant currency","value":24.6,"unit":"%","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma FY2026 net sales growth guidance (raised, constant currency)","value":"19–21","unit":"%","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma H1 2026 Injectable Aesthetics net sales","value":1437,"unit":"million USD","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma H1 2026 Fillers & Biostimulators net sales","value":611,"unit":"million USD","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma H1 2026 Fillers & Biostimulators growth at constant currency","value":10.5,"unit":"%","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma Q2 2026 Fillers & Biostimulators growth at constant currency","value":7.6,"unit":"%","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"AbbVie Q2 2026 Aesthetics net revenues","value":1282,"unit":"million USD","as_of":"2026-07-31","source":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm"},{"claim":"AbbVie Q2 2026 Juvederm global net revenues","value":245,"unit":"million USD","as_of":"2026-07-31","source":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm"},{"claim":"AbbVie Q2 2026 Juvederm operational growth","value":-6.6,"unit":"%","as_of":"2026-07-31","source":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm"},{"claim":"Galderma GLP-1 patient study: share saying face looked less gaunt at nine months","value":85.7,"unit":"%","as_of":"2025-07-17","source":"https://www.galderma.com/news/galderma-unveils-final-nine-month-data-medication-driven-weight-loss"},{"claim":"Galderma acquisition price for ZO Skin Health (cash)","value":1.5,"unit":"billion USD","as_of":"2026-10-15","source":"https://www.personalcareinsights.com/news/galderma-zo-skin-health-acquisition.html"},{"claim":"Galderma U.S. physician skincare share including ZO and Alastin","value":19,"unit":"%","as_of":"2026-10-15","source":"https://www.personalcareinsights.com/news/galderma-zo-skin-health-acquisition.html"},{"claim":"L'Oreal H1 2026 Dermatological Beauty like-for-like growth","value":11.3,"unit":"%","as_of":"2026-07-29","source":"https://www.loreal.com/en/press-release/finance/2026-half-year-results/"},{"claim":"BCG estimate of facial volume loss and laxity treatment market in five years","value":2,"unit":"billion USD","as_of":"2026-10-21","source":"https://uk.fashionnetwork.com/news/Beauty-giants-target-ozempic-face-as-boom-in-obesity-drugs-opens-new-market,1877889.html"},{"claim":"Caliway CBL-514 subjects in completed trials","value":544,"unit":"people","as_of":"2026-05-18","source":"https://www.prnewswire.com/apac/zh/news-releases/-eco-2026--cbl-514--glp-1r---302774493.html"},{"claim":"Animal study: weight regain after stopping tirzepatide alone (25.2% with CBL-514)","value":55.9,"unit":"%","as_of":"2026-05-18","source":"https://www.prnewswire.com/apac/zh/news-releases/-eco-2026--cbl-514--glp-1r---302774493.html"},{"claim":"Caliway CBL-0201WR U.S. Phase 2 planned enrollment","value":120,"unit":"people","as_of":"2026-08-31","source":"https://www.caliwaybiopharma.com/news-detail/Caliway_Investor_Conference_Key_Takeaways_20260831/"},{"claim":"Galderma Q2 2026 Injectable Aesthetics net sales","value":790,"unit":"million USD","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Share of U.S. aesthetics clinics expecting new patients from weight-loss medications (Medical Insight 2024, via Reuters)","value":53,"unit":"%","as_of":"2026-10-21","source":"https://uk.fashionnetwork.com/news/Beauty-giants-target-ozempic-face-as-boom-in-obesity-drugs-opens-new-market,1877889.html"},{"claim":"AbbVie Q2 2026 international Juvederm operational growth","value":-9.7,"unit":"%","as_of":"2026-07-31","source":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm"}],"sections":["01｜What actually goes missing from the face","02｜Same aisle, opposite directions: Galderma vs. Juvéderm","03｜Did the beauty giants really bet wrong?","04｜The Taiwan angle: Caliway attacks the same problem from the other side","References"],"references":[{"title":"Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market","source":"Reuters (via FashionNetwork","date":"2026-10-21","url":"https://uk.fashionnetwork.com/news/Beauty-giants-target-ozempic-face-as-boom-in-obesity-drugs-opens-new-market,1877889.html"},{"title":"Galderma reports record first half 2026 net sales of 3.134 billion USD","source":"Galderma","date":"2026-07-23","url":"https://www.galderma.com/news/galderma-H12026-performance"},{"title":"AbbVie Reports Second-Quarter 2026 Financial Results (Exhibit 99.1","source":"AbbVie / SEC","date":"2026-07-31","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm"},{"title":"Galderma unveils final nine-month data on facial aesthetic changes after medication-driven weight loss","source":"Galderma","date":"2025-07-17","url":"https://www.galderma.com/news/galderma-unveils-final-nine-month-data-medication-driven-weight-loss"},{"title":"Galderma Receives FDA Approval for New SCULPTRA Label","source":"Galderma","date":"2021-12-13","url":"https://www.galderma.com/index.php/news/galderma-receives-fda-approval-new-sculptra-label-offering-more-options-aesthetic-partners"},{"title":"Galderma buys ZO Skin Health for US$1.5B to expand dermatological skin care","source":"Personal Care Insights","date":"2026-10-15","url":"https://www.personalcareinsights.com/news/galderma-zo-skin-health-acquisition.html"},{"title":"2026 Half-Year Results","source":"L'Oréal","date":"2026-07-29","url":"https://www.loreal.com/en/press-release/finance/2026-half-year-results/"},{"title":"KFF Health Tracking Poll: Prescription Drug Costs and GLP-1 Use","source":"KFF","date":"2025-11-14","url":"https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/"},{"title":"Caliway presents CBL-514 plus GLP-1R agonist animal data at ECO 2026 (Chinese","source":"Caliway Biopharmaceuticals (PR Newswire","date":"2026-05-18","url":"https://www.prnewswire.com/apac/zh/news-releases/-eco-2026--cbl-514--glp-1r---302774493.html"},{"title":"Caliway H2 2026 investor conference key takeaways (Chinese","source":"Caliway Biopharmaceuticals","date":"2026-08-31","url":"https://www.caliwaybiopharma.com/news-detail/Caliway_Investor_Conference_Key_Takeaways_20260831/"}],"images":[{"alt":"Fig. 1｜The volume lost is in the fat layer","url":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra-en/figure-01.png"},{"alt":"Fig. 2｜Same injectables, opposite trends","url":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra-en/figure-02.png"},{"alt":"Fig. 3｜Where three giants placed their bets","url":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra-en/figure-03.png"},{"alt":"Fig. 4｜Slim everywhere, or only where you want","url":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-26）。Ozempic Face Is a Fat Gap, and Galderma Is Filling It。https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}